Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

While first line targeted therapies are the current standard of care treatment for non-small cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire resistance to these agents over time. Immune check-point inhibitors (ICIs) have improved the outcomes of metastatic NSC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karan Seegobin, Umair Majeed, Nathaniel Wiest, Rami Manochakian, Yanyan Lou, Yujie Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	targeted mutations immunotherapy c-MET RET BRAF ROS-1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9e3739d66fd3419fb78b4fe693d766c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e3739d66fd3419fb78b4fe693d766c2
record_format	dspace
spelling	oai:doaj.org-article:9e3739d66fd3419fb78b4fe693d766c22021-12-01T22:20:55ZImmunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR2234-943X10.3389/fonc.2021.750657https://doaj.org/article/9e3739d66fd3419fb78b4fe693d766c22021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.750657/fullhttps://doaj.org/toc/2234-943XWhile first line targeted therapies are the current standard of care treatment for non-small cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire resistance to these agents over time. Immune check-point inhibitors (ICIs) have improved the outcomes of metastatic NSCLC, however, its efficacy in those with targetable drivers is largely unknown. In this manuscript, we reviewed the published data on ICI therapies in NSCLC with ALK, ROS1, BRAF, c-MET, RET, NTRK, KRAS, and HER2 (ERBB2) alterations. We found that the objective response rates (ORRs) associated with ICI treatments in lung cancers harboring the BRAF (0–54%), c-MET (12–49%), and KRAS (18.7-66.7%) alterations were comparable to non-mutant NSCLC, whereas the ORRs in RET fusion NSCLC (less than10% in all studies but one) and ALK fusion NSCLC (0%) were relatively low. The ORRs reported in small numbers of patients and studies of ROS1 fusion, NTRK fusion, and HER 2 mutant NSCLC were 0–17%, 50% and 7–23%, respectively, making the efficacy of ICIs in these groups of patients less clear. In most studies, no significant correlation between treatment outcome and PD-L1 expression or tumor mutation burden (TMB) was identified, and how to select patients with NSCLC harboring actionable mutations who will likely benefit from ICI treatment remains unknown.Karan SeegobinUmair MajeedNathaniel WiestRami ManochakianYanyan LouYujie ZhaoFrontiers Media S.A.articletargeted mutationsimmunotherapyc-METRETBRAFROS-1Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	targeted mutations immunotherapy c-MET RET BRAF ROS-1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	targeted mutations immunotherapy c-MET RET BRAF ROS-1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Karan Seegobin Umair Majeed Nathaniel Wiest Rami Manochakian Yanyan Lou Yujie Zhao Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
description	While first line targeted therapies are the current standard of care treatment for non-small cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire resistance to these agents over time. Immune check-point inhibitors (ICIs) have improved the outcomes of metastatic NSCLC, however, its efficacy in those with targetable drivers is largely unknown. In this manuscript, we reviewed the published data on ICI therapies in NSCLC with ALK, ROS1, BRAF, c-MET, RET, NTRK, KRAS, and HER2 (ERBB2) alterations. We found that the objective response rates (ORRs) associated with ICI treatments in lung cancers harboring the BRAF (0–54%), c-MET (12–49%), and KRAS (18.7-66.7%) alterations were comparable to non-mutant NSCLC, whereas the ORRs in RET fusion NSCLC (less than10% in all studies but one) and ALK fusion NSCLC (0%) were relatively low. The ORRs reported in small numbers of patients and studies of ROS1 fusion, NTRK fusion, and HER 2 mutant NSCLC were 0–17%, 50% and 7–23%, respectively, making the efficacy of ICIs in these groups of patients less clear. In most studies, no significant correlation between treatment outcome and PD-L1 expression or tumor mutation burden (TMB) was identified, and how to select patients with NSCLC harboring actionable mutations who will likely benefit from ICI treatment remains unknown.
format	article
author	Karan Seegobin Umair Majeed Nathaniel Wiest Rami Manochakian Yanyan Lou Yujie Zhao
author_facet	Karan Seegobin Umair Majeed Nathaniel Wiest Rami Manochakian Yanyan Lou Yujie Zhao
author_sort	Karan Seegobin
title	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
title_short	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
title_full	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
title_fullStr	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
title_full_unstemmed	Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
title_sort	immunotherapy in non-small cell lung cancer with actionable mutations other than egfr
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/9e3739d66fd3419fb78b4fe693d766c2
work_keys_str_mv	AT karanseegobin immunotherapyinnonsmallcelllungcancerwithactionablemutationsotherthanegfr AT umairmajeed immunotherapyinnonsmallcelllungcancerwithactionablemutationsotherthanegfr AT nathanielwiest immunotherapyinnonsmallcelllungcancerwithactionablemutationsotherthanegfr AT ramimanochakian immunotherapyinnonsmallcelllungcancerwithactionablemutationsotherthanegfr AT yanyanlou immunotherapyinnonsmallcelllungcancerwithactionablemutationsotherthanegfr AT yujiezhao immunotherapyinnonsmallcelllungcancerwithactionablemutationsotherthanegfr
_version_	1718404117646278656

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

Ejemplares similares